These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15546123)

  • 1. Considerations in clinical trials of combination antifungal therapy.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S228-35. PubMed ID: 15546123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issues in clinical trials of prophylaxis of fungal infections.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S211-7. PubMed ID: 15546120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.
    Rex JH; Wingard JR; Wenzel R; Herbrecht R; Sobel J; Edwards JE
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S165-9. PubMed ID: 15546112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for invasive mycoses: evaluation of past clinical trial designs.
    Sobel JD
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S224-7. PubMed ID: 15546122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing?
    Vazquez JA
    Clin Infect Dis; 2008 Jun; 46(12):1889-901. PubMed ID: 18466092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of efficacy trials of cytokines in combination with antifungal drugs.
    Kullberg BJ; Oude Lashof AM; Netea MG
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S218-23. PubMed ID: 15546121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design.
    Singh N
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S200-6. PubMed ID: 15546118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions.
    Clemons KV; Stevens DA
    Curr Opin Infect Dis; 2006 Aug; 19(4):360-4. PubMed ID: 16804384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials of antifungal prophylaxis among patients undergoing surgery.
    Calandra T; Marchetti O
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S185-92. PubMed ID: 15546116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations.
    Lipsett PA
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S193-9. PubMed ID: 15546117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection.
    Almyroudis NG; Kontoyiannis DP; Sepkowitz KA; DePauw BE; Walsh TJ; Segal BH
    Clin Infect Dis; 2006 Dec; 43(11):1449-55. PubMed ID: 17083020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview: antifungal combination therapy.
    Sugar AM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1364-5. PubMed ID: 11890347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis.
    Bennett JE; Powers J; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P; Viscoli C; Walsh T
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S113-6. PubMed ID: 12679894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
    Baran R; Kaoukhov A
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G; Kontoyiannis DP
    Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
    Sobel JD
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination antifungal therapy: a critical review of the evidence.
    Ostrosky-Zeichner L
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():65-70. PubMed ID: 18430131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical trials in dermatology. Evaluation of the tolerability and efficacy of a topical antifungal agent in the treatment of superficial mycoses].
    Queille-Roussel C; Dahan C; Duteil L; Schaefer H; Revuz J; De Prost Y; Guillaume JC; Ortonne JP; Czernielewski J
    Therapie; 1991; 46(3):201-4. PubMed ID: 1792652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
    Muñoz P; Guinea J; Narbona MT; Bouza E
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S125-31. PubMed ID: 19013336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.